STOCK TITAN

Prelude Therapeutics narrows Q3 2026 loss to $12.5M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Prelude Therapeutics Inc (PRLD) reported third-quarter 2026 revenue of $5.647 million, down from $6.500 million a year earlier, while net loss narrowed to $12.544 million from $19.725 million. Net loss per share was $0.12, compared with $0.26. Research and development expense was $14.830 million, versus $21.708 million. Cash, cash equivalents, restricted cash and marketable securities totaled $142.7 million as of September 30, 2026; the company expects those resources to fund operations into the second quarter of 2028.

The FDA cleared Prelude to proceed with a Phase 1 study of PRT13722 under its Investigational New Drug Application in September 2026, and enrollment began in the fourth quarter. Initial proof-of-concept data are anticipated in the second half of 2027. In October, Prelude entered a clinical trial collaboration and supply agreement with Lilly to evaluate PRT13722 with abemaciclib and imlunestrant in the Phase 1 trial. The PRT12396 Phase 1 study continues enrolling patients with polycythemia vera and myelofibrosis. Updated preclinical data for the lead mCALR degrader antibody conjugate candidate were accepted for poster presentation at the ASH 67th Annual Meeting in December 2026.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Moderate pointQuarterly net loss narrowed to $12.544 million from $19.725 million.

Negative

  • Moderate pointQuarterly revenue fell to $5.647 million from $6.500 million.

Filing Explained

The JAK2V617F program remains subject to Incyte’s option agreement, due to expire in February 2027, with a possible three-month extension.

This 8-K furnishes Prelude Therapeutics' third-quarter release and investor presentation; its balance sheet reports 65,297,977 voting common shares outstanding at September 30, 2026, versus 48,225,493 at December 31, 2025, while non-voting shares were 14,728,135 on both dates. Against that larger voting-share base, a holder whose share count stayed the same would own a smaller percentage of voting shares.

The company says its JAK2V617F program remains subject to an exclusive option agreement with Incyte, set to expire in February 2027, with a possible three-month extension. Its presentation identifies a potential option-exercise decision in the first half of 2027.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Revenue $5.647 million Three months ended September 30, 2026; $6.500 million in the 2025 period.
Research and development expense $14.830 million Three months ended September 30, 2026; $21.708 million in the 2025 period.
General and administrative expense $5.082 million Three months ended September 30, 2026; $5.210 million in the 2025 period.
Net loss $12.544 million Three months ended September 30, 2026; $19.725 million in the 2025 period.
Net loss per share $0.12 Three months ended September 30, 2026; $0.26 in the 2025 period.
Cash, restricted cash and marketable securities $142.7 million As of September 30, 2026.
Expected cash runway Into the second quarter of 2028 Expected funding period for Prelude’s operations.
Investigational New Drug Application regulatory
"under its Investigational New Drug Application (IND)"
An investigational new drug application is a formal request made to regulatory authorities to begin testing a new medication in humans. It is a critical step in the drug development process, as approval indicates the drug has passed initial safety checks and can be studied further. For investors, this signals that a potential new treatment is progressing through its early testing stages, which can impact the company's future growth prospects.
proof of concept medical
"initial proof of concept data"
A proof of concept is a demonstration that shows a new idea, product, or method is feasible and can work as intended. It serves as evidence that an approach has potential value before full development or investment begins. For investors, it helps assess the likelihood of success and reduces uncertainty about whether the concept can deliver its promised benefits.
mutant-selective JAK2V617F inhibitor medical
"a mutant-selective JAK2V617F inhibitor in patients with PV and MF"
degrader antibody conjugate medical
"mCALR-targeted degrader antibody conjugates"
A degrader antibody conjugate is a laboratory-made protein that combines an antibody (which finds and binds a specific molecule on a cell) with a small attached agent that triggers the cell to break down that target. Think of it as a guided homing missile that not only marks a problem protein but also causes the cell’s disposal system to remove it; investors care because this approach can create highly specific, potentially more effective therapies with clearer paths to market value if safety and delivery are proven.
allosteric inhibitors technical
"novel allosteric inhibitors that bind into the JAK2 JH2 “deep pocket”"
Allosteric inhibitors are drugs or molecules that attach to a spot on a protein separate from its active site and change the protein’s shape so it works less effectively, like pressing a side button on a device to make it slow down. For investors, they matter because this approach can produce more selective, potentially safer therapies, create new intellectual property around hard-to-target molecules, and open alternative paths when direct-blocking drugs fail or cause resistance.
stock-based compensation financial
"non-cash expense related to stock-based compensation expense"
Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.
Revenue $5.647 million Down from $6.500 million in the 2025 period.
Research and development expense $14.830 million Down from $21.708 million in the 2025 period.
General and administrative expense $5.082 million Down from $5.210 million in the 2025 period.
Net loss $12.544 million Compared with a $19.725 million net loss in the 2025 period.
Net loss per share $0.12 Compared with $0.26 in the 2025 period.
Guidance

The company expects cash, cash equivalents, restricted cash and marketable securities to fund operations into the second quarter of 2028.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were PRLD’s third-quarter 2026 revenue and net loss?

Revenue was $5.647 million, compared with $6.500 million a year earlier, and net loss was $12.544 million, compared with $19.725 million.

How long does PRLD expect its cash to last?

The company reported $142.7 million in cash, cash equivalents, restricted cash and marketable securities as of September 30, 2026, and expects those resources to fund operations into the second quarter of 2028.

When does Incyte’s option agreement for PRLD’s JAK2V617F program expire?

The exclusive option agreement with Incyte is set to expire in February 2027, with a potential three-month extension.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001678660false00016786602026-11-162026-11-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

 

Prelude Therapeutics Incorporated

(Exact Name of Registrant as Specified in its Charter)

 

 

 

 

 

 

Delaware

 

001-39527

 

81-1384762

(State or other jurisdiction of
incorporation or organization)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

 

 

 

175 Innovation Boulevard

Wilmington, Delaware

 

19805

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (302) 467-1280

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

PRLD

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02 Results of Operations and Financial Condition.

 

On November 16, 2026, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 7.01 Regulation FD Disclosure.

The Company has prepared investor presentation materials with information about the Company, which it intends to use as part of investor presentations. A copy of the investor presentation materials to be used by management for presentations is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information in this Current Report on Form 8-K and in Exhibits 99.1 and 99.2 attached hereto is being furnished, but shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

 

 

Exhibit
Number

 

Description

99.1

 

Press Release dated November 16, 2026

99.2

 

Presentation

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL Document)

 


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

PRELUDE THERAPEUTICS INCORPORATED

 

 

 

 

 

Date: November 16, 2026

By:

/s/ Bryant Lim

 

 

Bryant Lim

 

 

Chief Financial Officer and Chief Legal Officer

 


Exhibit 99.1

img268059179_0.jpg

Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Enrollment of Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer is underway; initial proof of concept data anticipated in the 2nd half of 2027

 

Entered into a clinical trial collaboration and supply agreement with Lilly to evaluate PRT13722 in combination with Verzenio® and Inluriyo® in patients with HR+/HER2- breast cancer

 

Continued enrollment in Phase 1 Study of PRT12396, a mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

 

Preclinical data from mCALR-targeted degrader antibody conjugate (DAC) lead development candidate accepted for presentation at the American Society of Hematology (ASH) 68th Annual Meeting in December

 

Current cash runway expected into the second quarter of 2028 with $142.7 million in cash, cash equivalents, restricted cash and marketable securities as of September 30, 2026

 

WILMINGTON, Del., Nov. 16, 2026 (GLOBE NEWSWIRE) – Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the third quarter ended September 30, 2026 and provided an update on its R&D pipeline and other corporate developments.

“The first three quarters of 2026 have been a period of strong execution for Prelude,” said Kris Vaddi, Ph.D., Chief Executive Officer of Prelude. “We rapidly advanced two potential first-in-class programs into clinical development including PRT12396, a mutant-selective JAK2V617F inhibitor with disease-modifying potential in myeloproliferative neoplasms (MPNs) and PRT13722, a selective KAT6A degrader with the potential to improve the safety and efficacy of KAT6 inhibition, a clinically validated approach in HR+ breast cancer. In addition, we advanced our first-in-class mCALR degrader antibody conjugate (DAC) program into preclinical development with the selection of the development candidate, for mCALR+ MPNs, and we look forward to presenting its first preclinical data at ASH in December. With multiple clinical readouts expected over the next 12 to 18 months, we are well positioned to enter 2027 with the momentum to drive future growth of Prelude.”

 

Program Updates and Upcoming Milestones

 


Exhibit 99.1

Highly selective KAT6A oral degrader program

KAT6 is an emerging and recently validated target in the treatment of HR+ breast cancer. Prelude discovered and is developing highly potent, highly selective and orally bioavailable KAT6A selective degraders. Prelude believes that selectively degrading KAT6A has the potential for improved efficacy, tolerability and combinability with other agents relative to non-selective inhibitors of KAT6A/B.

 

In September 2026, the U.S. Food and Drug Administration (FDA) cleared the Company to proceed with a Phase 1 study under its Investigational New Drug Application (IND) for PRT13722, an oral KAT6A selective degrader being developed for the treatment of patients with HR+/HER2- breast cancer. The Company initiated enrollment into the Phase 1 study of PRT13722 in HR+ breast cancer in Q4 2026. The Company anticipates disclosure of initial proof of concept data from this study in the 2nd half of 2027.

 

Additionally, in October 2026, the Company entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company (“Lilly”) for supply of its CDK4/6 kinase inhibitor, abemaciclib, and its oral estrogen receptor antagonist, imlunestrant. The agreement supports the evaluation of Prelude’s clinical development candidate PRT13722, an oral KAT6A selective degrader, in combinations with abemaciclib and imlunestrant in the existing Phase 1 trial in patients with HR+/HER2- breast cancer.

 

Updated preclinical data from PRT13722 has been accepted for poster presentation at the 2026 San Antonio Breast Cancer Symposium taking place in San Antonio, TX, December 8-11, 2026. Additionally, the Company also has an accepted Trials in Progress poster presentation describing the current Phase 1 study of PRT13722. The abstracts can be found at San Antonio Breast Cancer Symposium® | SABCS 2026.

 

The Company previously presented preclinical data supporting PRT13722 at the AACR Annual Meeting 2026. The presentation can be found at Publications - Prelude Therapeutics.

 

Mutant selective JAK2V617F JH2 inhibitor program

JAK2V617F is the primary driver mutation responsible for disease progression in the majority of patients living with myeloproliferative neoplasms (MPNs). The mutation impacts approximately 95% of patients with polycythemia vera (PV), 60% of patients with essential thrombocythemia (ET) and 55% of patients with myelofibrosis (MF). Identifying JAK2 JH2 inhibitors that selectively target V617F+ cells has long been the goal for advancing the treatment of MPNs. Prelude has designed and identified novel allosteric inhibitors that bind into the JAK2 JH2 “deep pocket” where the V617F mutation resides. These candidates demonstrate mutant specific inhibition in multiple preclinical models of MPNs. Prelude believes this approach may have the potential to reduce mutant allele burden, slow or even reverse disease progression, and transform treatment outcomes for MPN patients.

 

PRT12396, is currently enrolling patients into a Phase 1 study of PRT12396, Prelude’s lead, mutant-selective JAK2V617F inhibitor in patients with PV and MF. The Company also continues to make progress advancing next generation development candidates with potential best-in-class selectivity profiles.

 


Exhibit 99.1

A Trials in Progress abstract describing the currently enrolling Phase 1 study of PRT12396 has been accepted for poster presentation at the American Society of Hematology (ASH) 67th Annual Meeting taking place in New Orleans, LA December 12-15, 2026. The abstract can be found on the ASH 2026 website ASH Annual Meeting & Exposition – Hematology.org.

 

The JAK2V617F inhibitor program is subject to an exclusive option agreement with Incyte announced in November 2025, which is set to expire in February of 2027, with potential for a 3 month extension.

 

Mutated calreticulin (mCALR) DAC discovery program

Mutant CALR is a neoantigen presented on the cell surface of malignant myeloid cells but not normal cells and is found in approximately 25-35% of patients with MF and essential thrombocythemia (ET). Recently, a mCALR-targeted monoclonal antibody demonstrated robust clinical activity in high-risk ET patients. Prelude is advancing mCALR-targeted degrader antibody conjugates (DACs) using the Company’s proprietary degrader payloads as a differentiated approach for patients with CALR mutations. This discovery program is wholly owned and controlled by Prelude.

 

The Company presented the preclinical data from the program at the European Hematology Association 2025 Congress in June and the American Society of Hematology (ASH) 67th Annual Meeting in December 2025. The presentations can be found at Publications – Prelude Therapeutics.

 

Updated preclinical data from the leading development candidate from this program has been accepted for poster presentation at the American Society of Hematology (ASH) 67th Annual Meeting taking place in New Orleans, LA December 12-15, 2026. The abstract can be found on the ASH 2026 website ASH Annual Meeting & Exposition – Hematology.org.

 

Degrader payloads for next generation DACs

Prelude is leveraging our expertise in targeted protein degradation to discover and develop novel degrader payloads for use with next generation DACs. We have developed highly potent SMARCA2/4 and CDK9 degrader payloads optimized for efficacy, tolerability and developability when coupled to a wide range of different antibodies. Building on our existing DAC partnership with AbCellera, the Company’s payloads and corresponding payload-linkers are available for licensing to additional partners to expand the reach of this new technology.

 

We have published preclinical data demonstrating that next generation DACs using Prelude degrader payloads have potential for significantly better in vivo efficacy and tolerability compared to traditional cytotoxic ADCs when tested head-to-head in xenograft models. These data can be found at: Publications – Prelude Therapeutics

 

Upcoming Investor Conference

The Company will participate in the 9th Annual Evercore Healthcare Conference taking place in Coral Gables, FL. On Wednesday, December 2, 2026 at 7:55 AM ET, Kris Vaddi, Ph.D., Chief

 


Exhibit 99.1

Executive Officer, Peggy Scherle, Ph.D., Chief Scientific Officer and Bryant Lim, Chief Financial Officer will participate in a fireside chat.

 

A live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations. The recording will be archived and available on the Company’s website for 90 days.

 

Third Quarter 2026 Financial Results 

Cash, Cash Equivalents, Restricted cash and Marketable securities:

Cash, cash equivalents, restricted cash and marketable securities as of September 30, 2026 were $142.7 million. The Company anticipates that its existing cash, cash equivalents, restricted cash and marketable securities will fund Prelude’s operations into the second quarter of 2028.

Research and Development (R&D) Expenses:

For the three months ended September 30, 2026, R&D expense decreased to $14.8 million from $21.7 million for the prior year period. Included in the R&D expense for the three months ended September 30, 2026 was $0.9 million of non-cash expense related to stock-based compensation expense, including employee stock options, compared to $1.4 million for the three months ended September 30, 2025. Along with the decrease in stock-based compensation expense, the decrease was primarily related to lower expense incurred for our SMARCA2 clinical trials, which we paused in 2025, along with a decrease in employee related expenses due to a workforce reduction in the second half of 2025. Research and development expenses may fluctuate from period to period depending upon the stage of certain projects and the level of preclinical and clinical trial-related activities.

General and Administrative (G&A) Expenses:

For the three months ended September 30, 2026, G&A expenses decreased to $5.1 million from $5.2 million for the prior year period. Included in general and administrative expenses for the three months ended September 30, 2026, was $1.1 million of non-cash expense related to stock-based compensation expense, including employee stock options, compared to $1.0 million for the three months ended September 30, 2025. The decrease in general and administrative expenses was primarily due to a decrease in professional fees and employee-related expenses.

Net Loss:

For the three months ended September 30, 2026, net loss was $12.5 million, or $0.12 per share compared to $19.7 million, or $0.26 per share, for the prior year period. Included in the net loss for the three months ended September 30, 2026, was $2.0 million of non-cash expenses related to the impact of expensing share-based payments, including employee stock options, as compared to $2.4 million for the same period in 2025.

 


Exhibit 99.1

About Prelude Therapeutics

Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need. Our pipeline features highly selective KAT6A degraders and JAK2V617F mutant selective inhibitors -- new approaches to clinically validated targets with transformative potential for patients. We are leveraging our expertise in targeted protein degradation to create and develop next generation degrader antibody conjugates (DACs) with novel payloads, including a first-in-class mCALR-targeted DAC. Our mission is to deliver practice-changing cancer medicines. For more information, visit preludetx.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities for Prelude’s product candidates, the potential safety, efficacy, benefits and addressable market for Prelude’s product candidates, the expected timeline for clinical trial results for Prelude’s product candidates, and the sufficiency of Prelude’s cash runway into the second quarter of 2028. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” “schedule,” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on the Company’s current expectations and projections about future events and various assumptions. Although Prelude believes that the expectations reflected in such forward-looking statements are reasonable, Prelude cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Prelude's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Prelude's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, clinical trial sites and our ability to enroll eligible patients, supply chain and manufacturing facilities, Prelude’s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, Prelude's ability to fund development activities and achieve development goals, Prelude's ability to protect intellectual property, and other risks and uncertainties described under the heading "Risk Factors" in Prelude’s Annual Report on Form 10-K for the year ended December 31, 2025, its Quarterly Reports on Form 10-Q and other documents that Prelude files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Prelude undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof, except as may be required by law.

 


Exhibit 99.1

PRELUDE THERAPEUTICS INCORPORATED

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

 

 

Three Months Ended September 30,

 

(in thousands, except share and per share data)

 

2026

 

 

2025

 

Revenue

$

5,647

 

 

$

6,500

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

Research and development

 

14,830

 

 

 

21,708

 

General and administrative

 

5,082

 

 

 

5,210

 

Total operating expenses

 

 

19,912

 

 

 

26,918

 

Loss from operations

 

 

(14,265)

 

 

 

(20,418

)

Other income, net

 

1,721

 

 

 

693

 

Net loss

 

$

(12,544)

 

 

$

(19,725

)

Per share information:

 

 

 

 

 

 

Net loss per share of common stock, basic and diluted

$

(0.12)

 

 

$

(0.26

)

Weighted average common shares outstanding, basic
   and diluted

 

103,091,149

 

 

 

76,132,337

 

Comprehensive loss:

 

 

 

 

 

 

Net loss

 

$

(12,544)

 

 

$

(19,725

)

Unrealized (loss) gain on marketable securities, net of tax

 

(306)

 

 

 

3

 

Comprehensive loss

 

$

(12,850)

 

 

$

(19,722

)

 

 

 

 

 

 

 

 

 


Exhibit 99.1

 

PRELUDE THERAPEUTICS INCORPORATED

BALANCE SHEETS

 

(in thousands, except share data)

 

September 30,
2026

 

 

December 31,
2025

 

Assets

 

(unaudited)

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

$

23,412

 

 

$

35,256

 

Marketable securities

 

116,589

 

 

 

67,958

 

Prepaid expenses and other current assets

 

2,426

 

 

 

2,478

 

Total current assets

 

 

142,427

 

 

 

105,692

 

Restricted cash

 

2,725

 

 

 

3,235

 

Property and equipment, net

 

4,063

 

 

 

5,113

 

Right-of-use asset

 

25,996

 

 

 

27,165

 

Prepaid expenses and other non-current assets

 

274

 

 

 

110

 

Total assets

 

$

175,485

 

 

$

141,315

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

$

2,971

 

 

$

3,983

 

Accrued expenses and other current liabilities

 

8,563

 

 

 

12,533

 

Deferred revenue

 

19,601

 

 

 

33,734

 

Operating lease liability

 

2,796

 

 

 

2,744

 

Total current liabilities

 

 

33,931

 

 

 

52,994

 

Deferred revenue, net of current portion

 

-

 

 

 

1,798

 

Other liabilities

 

2,655

 

 

 

2,841

 

Operating lease liability

 

14,763

 

 

 

15,045

 

Total liabilities

 

 

51,349

 

 

 

72,678

 

Commitments (Note 8)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Voting common stock, $0.0001 par value: 487,149,741 shares authorized; 65,297,977 and 48,225,493 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively

 

7

 

 

 

5

 

Non-voting common stock, $0.0001 par value: 112,850,259 shares authorized; 14,728,135 shares issued and outstanding at both September 30, 2026 and December 31, 2025

 

1

 

 

 

1

 

Additional paid-in capital

 

844,572

 

 

 

751,684

 

Accumulated other comprehensive (loss) income

 

(533)

 

 

 

8

 

Accumulated deficit

 

(719,911)

 

 

 

(683,061

)

Total stockholders’ equity

 

 

124,136

 

 

 

68,637

 

Total liabilities and stockholders’ equity

 

$

175,485

 

 

$

141,315

 

 

Investor Contact:
Robert A. Doody, Jr.
Senior Vice President, Investor Relations

Prelude Therapeutics Incorporated

484.639.7235

rdoody@preludetx.com

 


Slide 1

Corporate Presentation November 2026 Exhibit 99.2


Slide 2

This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities for Prelude’s product candidates and milestones, the potential safety, efficacy, benefits and addressable market for Prelude Therapeutics Incorporated's (the "Company") product candidates. Any statements contained herein or provided orally that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by such terminology as ‘‘believe,’’ ‘‘may,’’ ‘‘will,’’ ‘‘potentially,’’ ‘‘estimate,’’ ‘‘continue,’’ ‘‘anticipate,’’ “aim,” “associated,” ‘‘intend,’’ ‘‘could,’’ ‘‘would,’’ ‘‘project,’’ ‘‘plan,’’ ‘‘expect’’ and similar expressions that convey uncertainty of future events or outcomes, although not all forward-looking statements contain these words. Statements, including forward-looking statements, speak only to the date they are provided (unless an earlier date is indicated).  These forward-looking statements are based on the beliefs of our management as well as assumptions made by and information currently available to us. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. If such assumptions do not fully materialize or prove incorrect, the events or circumstances referred to in the forward-looking statements may not occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations, except as required by law. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements.  Additional risks and uncertainties that could affect our business are included under the caption “Risk Factors” in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2025. This presentation also contains estimates and other statistical data made by independent parties and by us relating to product growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. This presentation concerns drugs that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration (the "FDA"). They are currently limited by Federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated. Forward Looking Statements & Disclaimers


Slide 3

Target first, modality flexible approach to cancer drug discovery focused on validated biologic pathways Fully resourced to deliver key data catalysts across multiple programs over the next 12-24 months 3 Patients Living with Cancer Deserve Better Therapies Our mission is to deliver practice-changing cancer medicines Experienced management team with a track record of clinical and commercial success


Slide 4

Kris Vaddi, PhD Chief Executive Officer Andrew Combs, PhD Chief Chemistry Officer Sean Brusky, MBA Chief Business & Strategy Officer Peggy Scherle, PhD Chief Scientific Officer Bryant Lim, J.D. Chief Financial Officer, Chief Legal Officer, Secretary Experienced Leadership Team With Proven Track Record Charles Morris, MD Chief Medical Officer


Slide 5

POTENTIAL INDICATIONS DISCOVERY IND-ENABLING PHASE 1 PROGRAM INTEREST ANTICIPATED MILESTONES KAT6A Selective Degraders HR+ breast cancer, other malignancies Initial Proof of Concept Data 2nd Half 2027 JAK2V617F Mutant Selective JH2 Inhibitors VF+ Myeloproliferative Neoplasms (MPNs) (MF, PV, ET) INCY Option Expiration First Half 2027 Phase 1 Early Data 2027 mCALR Precision DACs CALR-mutated MPNs (ET, MF) Prelude wholly owned Preclinical Data ASH 2026 Degrader Payloads for DACs Broad utility across multiple indications . . . Additional Partnerships Advancing Multiple Differentiated Programs for Clinically Validated Targets JAK2, janus kinase 2; JH2, JAK2 homology domain 2 (pseudokinase regulatory domain); VF+, V617F mutated; MPNs, myeloproliferative neoplasms; MF, myelofibrosis; PV, polycythemia vera; ET, essential thrombocythemia; HR+, hormone receptor positive; DAC, degrader antibody conjugate; mCALR, mutated calreticulin 1 - Exclusive option agreement with Incyte (Nov. 2025); 2 - DAC Discovery Collaboration with AbCellera (Nov. 2023, amended and expanded 2H 2025) Proprietary degrader payloads available for licensing to partners developing next generation DACs 1 2 PRT12396 PRT13722 Prelude wholly owned


Slide 6

Three Key Programs With Data Catalysts Over the Next 12-24 Months JAK2V617F (PRT12396) Mutant Selective Inhibitor Potentially transformative JAK2V617F allosteric JH2 inhibitor designed to reduce mutant allele burden and modify the course of disease progression in patients with myeloproliferative neoplasms (MPNs) KAT6A (PRT13722) Highly Selective Oral Degrader First-in-class KAT6A degrader with >1000x selectivity over KAT6B – a differentiated modality and profile with potential to become a new backbone therapy in the treatment of HR+ breast cancer mCALR Precision DAC Next Generation Precision DAC First-in-class mutated calreticulin (mCALR) DAC (Degrader Antibody Conjugate) that is equipotent on CALR Type 1 & 2 mutations and >100x more potent compared to clinical-stage CALR antibodies for patients with MPNs


Slide 7

Patients With HR+/HER2- Breast Cancer Need Better Therapies 1. SEER Cancer Stats: Breast Cancer Subtypes, Global Data (EU5 only); NCCN Guidelines V5.2025 (accessed March 2026); Risk stratification varies based on guidelines and staging tools used; 2. Khatpe AS, et al., Cancers 2021. 3. Reinert T, et al., Ther Adv Med Oncol 2015. 4. Brufsky A, et al., Clin Breast Cancer 2019. 5. Prelude estimates based on clinical trial data and package inserts. 1L: 1st line; 2L: 2nd line; 3L: 3rd line SoC: Standard of Care; AI: aromatase inhibitors, ET: endocrine therapy (AI, SERM, SERD, etc.) Suboptimal Treatments  Disease Progression  Acquired Mutations  Worsening Outcomes Well-tolerated treatments are needed that span mutational subtypes, combinations, and lines of care Early-Stage Advanced / Metastatic Low Risk (aromatase inhibitors) High Risk (AI or ET +/- CDK4/6i) 1L 2L 3L+ ~1/3 of early-stage patients ultimately recur or progress to metastatic disease 1 >50% of advanced stage patients experience disease progression or death within 2 years on current SoC 2-4  Combinations are now SoC (ET + CDK4/6 +/- mutation-targeted Tx) Treatment Duration 1,5 5+ years 5+ years 9-36+ mo. 6-12+ mo. 3-9+ mo. Chemotherapy, ADCs, clinical trial


Slide 8

Pfizer Validated KAT6 as a Target, but Showed the Limits of Dual A/B Inhibition Limited clinical activity as monotherapy (5mg): 11.4% ORR; 3.3 mo mPFS Initial ORR/PFS in combo with fulvestrant (5mg, 500mg FUL): 37.2% ORR; 10.3 mo mPFS … with notable limitations 1,2: Neutropenia (Gr 3/4) 46% Dysgeusia (Gr 1/2) 84% Dose Reductions 56% Dose intensity limits efficacy Combination with current backbone therapies, especially CDK4/6 inhibitors, will be challenging Unclear path to first-line treatment settings Initial validation has opened a crowded fast-follower field, but nearly all other players are pursuing dual KAT6A/B inhibitors and are likely to face similar limitations 1. P LoRusso, et al., Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+/HER2− metastatic breast cancer (mBC): Results from phase 1 study to support the recommended phase 3 dose (RP3D) ASCO 2025 Annual Meeting, J Clin Oncol 43, 1020 (2025) ; 2. 78% of dose reductions were attributable to neutropenia (44% of patients required dose reductions due to neutropenia), R Layman, et. al., J Clin Oncol 44, 2026 (suppl 16; abstr 1068) Initial clinical profile of prifetrastat established in Phase 1/2 trial 1:


Slide 9

Prelude AACR 2026 poster presentation (access here); Pfizer reference - Sharma S, et al., Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer. Cell Chemical Biology. 2023; 30(10):1191-1210.e20. KAT6A Degradation May Be a Better Approach than KAT6A/B Dual Inhibition A KAT6A selective degrader has potential to drive deeper biologic suppression of key oncogenic drivers and a better therapeutic index in HR+ breast cancer KAT6A/B Inhibitor KAT6A Degrader EAF6 ING5 BRPF1 EAF6 ING5 BRPF1 KAT6B KAT6A degraded, complex collapses EAF6 ING5 BRPF1 KAT6B KAT6B spared, function retained KAT6A ER Signaling PR Signaling MYC Signaling Healthy Blood Cell Production ER Signaling PR Signaling MYC Signaling KAT6A inhibited KAT6B inhibited Healthy Blood Cell Production ING5 EAF6 KAT6A BRPF1


Slide 10

Prelude AACR 2026 poster presentation (access here); 1. Once-daily dosing projected based on preclinical PK and modeling; combinability based on preclinical data; 2. Mice harboring ZR-75-1 xenografts were treated with PRT13722; effects on tumor growth are shown; 3. Mice harboring T47-D xenografts were treated with PRT13722 or a racemic mixture of PRT13722*; well-tolerated with no observed body weight loss in animals in either model. PRT13722: Our First-in-Class KAT6A Selective Degrader Candidate SELECTIVE >1,000X selectivity for KAT6A over KAT6B POTENT Sub-nanomolar degrader (0.3 nM DC50) ORAL Convenient once-daily oral dosing 1 COMBINABLE Demonstrated synergy with ET, CDK4/6i & PI3Kαi at well-tolerated doses 1 Complete tumor regressions as monotherapy across multiple preclinical HR+ breast cancer models KAT6A Amplified (ZR-75-1)2 KAT6A Non-amplified (T-47-D)3 3 mg/kg*, PO, QD 1 mg/kg, PO, QD Engineered to be a potential part of backbone therapy for the treatment of HR+ breast cancer 0.04 mg/kg, PO, QD 0.2 mg/kg, PO, QD 1 mg/kg, PO, QD 5 mg/kg, PO, QD vehicle vehicle


Slide 11

PRT13722 Monotherapy Demonstrates Better Efficacy Head-to-Head Versus Prifetrastat in Preclinical Studies Prelude AACR 2026 poster presentation (access here); mice harboring T47-D xenografts were treated with PRT13722 or a racemic mixture of PRT13722*; effects on tumor growth shown. # TGI, Tumor Growth Inhibition (n = 8 or 16 mice per study); ^ % of T47-D tumors that regressed below baseline on Day 31/32 of studies. ** <0.01 p-value t-test Better Efficacy as Monotherapy vs. Prifetrastat + Fulvestrant in Combination Class Treatment % Tumors Regressed^ Monotherapy prifetrastat, 1 mg/kg 0% PRT13722, 1 mg/kg 50% PRT13722*, 3 mg/kg 75% + ET prifetrastat, 1 mg/kg + fulvestrant 13% PRT13722, 1 mg/kg + fulvestrant 88% Fulvestrant (25 mg/kg, SC, QW+LD) >50-fold Lower exposure (AUC) required for comparable efficacy to prifetrastat Better Efficacy Head-to-Head vs. Prifetrastat Treatment Day 28 TGI# Plasma Cave (µM) prifetrastat, 1 mg/kg, QD 59% 5.50 PRT13722*, 0.3 mg/kg, QD 67% 0.09 PRT13722, 1 mg/kg, QD 89% 0.35 PRT13722*, 3 mg/kg, QD 101% 1.32 HR+/HER2-, PIK3CA H1047R (T47-D)


Slide 12

PRT13722 Completely Eradicates Tumors in Treatment Refractory PDX Models: 100% Complete Response Rate as Monotherapy Prelude AACR 2026 poster presentation (access here); Prelude Data On File; Off-tx indicates treatment cessation HR+/HER2- CDK4/6 + ET Refractory In Vivo PDX (ST3164B) 100% of test animals achieved complete and durable responses across two PDX studies Responses persisted following treatment cessation in treatment refractory models Minimal observed body weight changes in either study HR+/HER2- Post-Chemo, Post-Tamoxifen In Vivo PDX (ST353) Post- CDK4/6 + ET Post- Chemo, Tamoxifen


Slide 13

Prelude Data on File; CFU-GM, Colony-Forming Unit-Granulocyte/Macrophage, myeloid progenitor cells found in bone marrow; LD, low dose; HD, high dose; CD, clinical dose *Study conducted with PRT13722 or a racemic mixture of PRT13722; Prelude AACR 2026 poster presentation (access here) PRT13722 Lowers Bone-Marrow Toxicity Potential by Sparing KAT6B SELECTIVITY >1,000X selective for KAT6A over KAT6B IMPACT KAT6B spared in the bone marrow RESULT Limited effects on neutrophils in preclinical models OUTCOMES Maintain higher dose intensity and ability to combine with CDK4/6i's Ex Vivo Dose Response of CFU-GM Selectivity may enable improved combinability with standard-of-care therapies Plot of In Vivo Efficacy vs. Impact on CFU-GM Viability PRT13722 vs. prifetrastat


Slide 14

Prelude AACR 2026 poster presentation (access here) PRT13722 Shows Synergistic Potential in Combo with Current SoC Agents ENDOCRINE THERAPY fulvestrant & oral SERDs ✓ Synergistic CDK4/6 INHIBITORS ribociclib, abemaciclib ✓ Synergistic PI3Kα INHIBITORS alpelisib, inavolisib ✓ Synergistic prifetrastat Current Standard of Care Agents fulvestrant (ET/SERD) abemaciclib (CDK4/6i) alpelisib (PI3Kαi) PRT13722 1 mg/kg


Slide 15

Robust Phase 1 Designed to Show PRT13722 is in a Class of Its Own 1 2 3 2026 2027 2028 Phase 1 Dose Escalation - Monotherapy and Combinations IND cleared Ph 1 started 4Q 2026 HR+/HER2- BC (Monotherapy) Phase 1 Dose Escalation Mono & Combo Expansion Cohorts DL(n) (N=3-6) DL1 (N=3-6) DL2 (N=3-6) Mono, fulvestrant combo, fulvestrant/CDK4/6 combo and oral SERD combo Key Data Readouts in 2027/2028 ORR as mono and combo, durability of response Molecular response and ctDNA profiling Safety, tolerability and dose intensity as mono and in combo with first-line agents HR+/HER2- BC (+ fulvestrant) DL(n) (N=3-6) DL1 (N=3-6) DL2 (N=3-6) Demonstrate Differentiated Safety Profile Profile Monotherapy & Combination Efficacy Inform the Registration Path Backfill / combo cohorts can be initiated at any dose level Trial schema is illustrative.


Slide 16

See press release: https://investors.preludetx.com/news-releases/ Clinical Trial Collaboration and Supply Agreement with Lilly Now in Effect CDK4/6 combo enables evaluation with agent used in frontline treatment of HR+/HER2- mBC Phase 1 supply of abemaciclib (CDK4/6 inhibitor) and imlunestrant (oral SERD) Oral SERD combo enables evaluation with oral endocrine therapy Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer   Combination cohorts are part of Prelude’s Phase 1 trial evaluating PRT13722 in patients with HR+/HER2- breast cancer, on track to initiate enrollment in the fourth quarter of 2026 The collaboration is underpinned by pre-clinical data that demonstrate monotherapy efficacy for PRT13722 and synergy with both CDK4/6 inhibitors and endocrine therapies across multiple HR+ breast cancer models Prelude maintains full global development and commercial rights to PRT13722 as a wholly owned program.


Slide 17

A New Backbone Therapy for HR+ BC Could Address a $40B+ Total Market Early-Stage Advanced / Metastatic Low Risk (60-70%) High Risk (30-40%) 1L 2L 3L+ $5-10B+ Potential peak sales (US/EU5) 1L–3L+ advanced BC only $40B+ Total addressable market (US/EU5) incl. neo/adjuvant use in early-stage disease Drug-Treated Prevalence 1,5 150k+ 125k+ 90k+ 75k+ 35k+ Treatment Duration 5 5+ years 5+ years 9-36+ mo. 6-12+ mo. 3-9+ mo. 1. SEER Cancer Stats: Breast Cancer Subtypes, analyst estimates (EU5 only); NCCN Guidelines V5.2025 (accessed: March 2026); Risk stratification varies based on guidelines and staging tools used; 2. Khatpe AS, et al., Cancers 2021. 3. Reinert T, et al. Ther Adv Med Oncol 2015. 4. Brufsky A, et al., Clin Breast Cancer 2019. 5. Prelude estimates based on clinical trial data and package inserts. 1L: 1st line; 2L: 2nd line; 3L: 3rd line HR+/HER2- is the most common subtype of the most common cancer in women


Slide 18

Prelude is advancing a highly selective oral KAT6A degrader (PRT13722) with potential to become a new backbone therapy in the treatment of HR+ breast cancer PRT13722 has potential to achieve more robust efficacy relative to KAT6A/B inhibitors as monotherapy or in combination with commonly used agents in breast cancer PRT13722 was well-tolerated in preclinical studies, supporting potential to differentiate based on overall safety and combinability with standard of care agents across lines of therapy Initial Phase 1 designed to demonstrate early proof-of-concept on differentiated profile as both monotherapy and in combination with current standard-of care agents IND application clearance received; enrollment of Phase 1 study of PRT13722 in patients with HR+/HER2- breast cancer is underway; initial proof of concept data anticipated in 2nd half of 2027. Prelude’s First-in-Class KAT6A Selective Degrader Program Summary


Slide 19

Three Key Programs With Data Catalysts Over the Next 12-24 Months JAK2V617F (PRT12396) Mutant Selective Inhibitor Potentially transformative JAK2V617F allosteric JH2 inhibitor designed to reduce mutant allele burden and modify the course of disease progression in patients with myeloproliferative neoplasms (MPNs) KAT6A (PRT13722) Highly Selective Oral Degrader First-in-class KAT6A degrader with >1000x selectivity over KAT6B – a differentiated modality and profile with potential to become a new backbone therapy in the treatment of HR+ breast cancer mCALR Precision DAC Next Generation Precision DAC First-in-class mutated calreticulin (mCALR) DAC (Degrader Antibody Conjugate) that is equipotent on CALR Type 1 & 2 mutations and >100x more potent compared to clinical-stage CALR antibodies for patients with MPNs


Slide 20

DL Paz et al. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood (2023) 141 (16): 1909–1921. F. Passamonte et.al., Clinical Significance of JAK2 V617F mutant allele burden; Haematologica 2009 Jan;94(1):7–10; MPNs, myeloproliferative neoplasms; MF, myelofibrosis; PV, polycythemia vera; ET, essential thrombocythemia Biomarker-Directed Therapy is the New Frontier in the Treatment of MPNs Myeloproliferative Neoplasms Are a Genetically Driven Spectrum of Diseases A JAK2V617F mutant selective inhibitor has disease modifying potential Increasing genomic complexity Worsening outcomes V617F mutation leads to constitutive JAK-STAT signaling, uncontrolled proliferation, and potentially to  disease progression (ET/PV  MF  AML) JAK2V617F is the primary driver mutation in MPNs Primary driver mutations: JAK2V617F, Calreticulin (mCALR), MPL Additional modifier mutations: ASXL1, TET2, IDH1/2, ….


Slide 21

Current JAK Inhibitors Do Not Selectively Target JAK2V617F+ Mutant Clones 1-4. Package Inserts; 5. Guglielmelli et al. Blood (2022) 140: 1788–1789. 6. Harrison et al. J.Clin Oncol. 2023; 41(19);3544 Molecular response is associated with improved patient outcomes and event-free survival (EFS).6 JAK2V617F mutant selective inhibitors have greater potential to deliver molecular responses. No JAK inhibitors are currently approved in first-line PV or ET DLTs (cytopenias) with JAK inhibitors limit dose intensity and ability to achieve molecular response   Ruxolitinib takes >5 years to achieve meaningful mutant allele burden reduction5 Current JAK inhibitors provide spleen and symptom benefits in MF with limited impact on disease course Ruxolitinib1 Fedratinib2 Pacritinib3 Momelotinib4 Targets JAK1, JAK2 JAK2, JAK1 (weak), FLT3 JAK2, FLT3, IRAK1, ACVR1 JAK1, JAK2, ACVR1 Indicated use Intermediate or high-risk MF, 2L+ PV Intermediate-2 or high-risk MF Intermediate or high-risk MF w/ platelet count <50x109/L Intermediate or high-risk MF with anemia Key liabilities, labeled risks Thrombocytopenia, anemia, infection, weight gain GI toxicity, Wenicke encephalopathy Hemorrhage, CV events, GI toxicity Anemia, thrombocytopenia


Slide 22

Source: NCI SEER Database (accessed June 2026), Blood Cancer United (LLS) Facts & Figures. * Prevalence of V617F mutation in Primary Myelofibrosis (PMF); prevalence in post-PV/ET MF is 85-95%+. A JAK2V617F Mutant Selective Inhibitor Has Broad Potential in the Treatment of Myeloproliferative Neoplasms (MPNs) Polycythemia Vera (PV) ~150,000 U.S. patients ~95% mutated → ~142,000 Essential Thrombocythemia (ET) ~140,000 U.S. patients ~60% mutated → ~84,000 Myelofibrosis (MF) ~20,000 U.S. patients ~55%* mutated → ~12,000 JAK2V617F is the dominant driver mutation across all three main MPN subtypes ~238,000 patients with JAK2V617F-driven MPNs in the U.S. alone ~310,000 patients in the U.S. living with a MPN (20,000+ newly diagnosed each year) JAK2V617F Mutation Prevalence in MPNs


Slide 23

Prelude Scientists Recently Discovered the First Known JAK2 Inhibitors that Bind in the JAK2 JH2 “Deep Pocket” Where the V617F Mutation Resides Prelude JAK2 JH2 Inhibitors Bind into the “Deep Pocket” Adjacent to V617F Mutation Allosteric JH2 Regulatory Domain vs. JH1 Catalytic Domain Prelude Data on File


Slide 24

PRT12396: Our Lead JAK2V617F Mutant Selective JH2 Inhibitor *** p<0.001 by Mann-Whitney U test BaF3 model Prelude ASH Annual Meeting 2025 oral presentation (access here) Equivalent or better efficacy to ruxolitinib in preclinical in vivo models at well-tolerated doses PRT12396 has potential for improved efficacy, tolerability and disease modification in JAK2V617F+ MPNs >200-fold selectivity over JAK1 and TYK2, plus clean profile in KinomeSCAN™ panel of >450 kinases Minimal impact on JAK2 wild-type (WT) cells at doses demonstrating anti-proliferative effects in JAK2VF+ MPN cells >70% reduction in splenomegaly and normalization of pathogenic cytokines in vivo PRT12396 (nM) PRT12396 (nM)


Slide 25

PRT12396: Designed to Overcome the Limitations of Current JAK Inhibitors * Dotted lines represent proliferation IC50 values from SET2 (VF) and UT-7 (WT) 7-day proliferation assay Prelude ASH Annual Meeting 2025 oral presentation (access here) SELECTIVITY Plasma exposures at efficacious doses remain below JAK2 WT IC50 IMPACT Efficacy AUC is 10-fold lower than toxicity AUC in vivo RESULT Limited effects on reticulocytes at efficacious doses Potential for efficacious exposures at well-tolerated doses could enable PRT12396 to maintain dose intensity over an extended duration of therapy OUTCOMES Potential for improved efficacy and tolerability No evidence of wild-type JAK2 inhibition in 2-week rat toxicology study at doses providing efficacious exposures * Reticulocyte inhibition only at high dose, with full recovery by day 15


Slide 26

PRT12396: Phase 1 Study Now Enrolling MF and PV Cohorts in Parallel MF 2026 2027 2028 Phase 1 Expansion Cohorts Phase 1 (enrolling MF & PV cohorts in parallel) Phase 1 Dose Escalation Expansion Cohorts DL(n) (N=3-6) DL1 (N=3-6) DL2 (N=3-6) Expansion in MF & PV at Dose OBJECTIVE CHR rate, durability (24 week) and molecular response rate (allele burden reduction) Spleen and symptom benefit Data generation in preparation for first registrational trial(s) Trial schema is illustrative. MPNs, myeloproliferative neoplasms; MF, myelofibrosis; PV, high risk polycythemia vera; CHR, complete hematologic response; DL, dose level PV DL(n) (N=3-6) DL1 (N=3-6) DL2 (N=3-6) MF & PV cohorts enrolling in parallel 1 2 3 Demonstrate Differentiated Safety Profile Profile Efficacy in MF & PV incl. Molecular Response Inform the Registration Path


Slide 27

Exclusive option agreement with Incyte (announced November 2025) Time-Bound Option Agreement With Incyte In Effect Into 1H 2027


Slide 28

Three Key Programs With Data Catalysts Over the Next 12-24 Months JAK2V617F (PRT12396) Mutant Selective Inhibitor Potentially transformative JAK2V617F allosteric JH2 inhibitor designed to reduce mutant allele burden and modify the course of disease progression in patients with myeloproliferative neoplasms (MPNs) KAT6A (PRT13722) Highly Selective Oral Degrader First-in-class KAT6A degrader with >1000x selectivity over KAT6B – a differentiated modality and profile with potential to become a new backbone therapy in the treatment of HR+ breast cancer mCALR Precision DAC Next Generation Precision DAC First-in-class mutated calreticulin (mCALR) DAC (Degrader Antibody Conjugate) that is equipotent on CALR Type 1 & 2 mutations and >100x more potent compared to clinical-stage CALR antibodies for patients with MPNs


Slide 29

Sources: NCI SEER Database (accessed June 2026), Blood Cancer United (LLS) Facts & Figures; J.How et. al., Mutant calreticulin in myeloproliferative neoplasms, Blood (2019) 134 (25): 2242–2248; Tefferi A, et al. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 2014 Aug;89(8):E121-4. doi: 10.1002/ajh.23743. Epub 2014 May 16. PMID: 24753125. Mutated Calreticulin (mCALR) Represents a Promising Target for a Next Generation Degrader Antibody Conjugate (DAC) Essential Thrombocythemia (ET) ~140,000 prevalent U.S. patients ~25% mutated → ~35,000 Myelofibrosis (MF) ~20,000 prevalent U.S. patients ~35% mutated → ~7,000 mCALR is emerging as a validated target in MPNs for biomarker-directed therapy ~42,000 patients with mCALR-driven ET or MF in the U.S. alone CALR Mutation Prevalence in MPNs Mutant CALR is a neoantigen presented on the surface of malignant cells but not normal cells ~45-55% Type I mutations (e.g., 52-bp deletion) ~30-40% Type II mutations (e.g., 5-bp insertion) CALR mutations drive constitutive JAK/STAT signaling and uncontrolled proliferation of myeloid cells leading to increased risk of disease progression


Slide 30

INCA989 Validated mCALR as a Target, Albeit with Notable Limitations 83% of patients achieved complete hematological response (CHR) at doses ≥ 400mg IV, with 47% durable CHR ≥12 weeks 52% and 31% of patients achieved >25% and >50% best mCALR variant allele frequency (VAF) reduction, respectively Generally well-tolerated with 93% of patients remaining on treatment at time of analysis … with notable limitations 1-3: Go Forward Ph 3 Dose (ET) 750mg - 2500mg Q2W IV (escalation) Activity in Non-Type 1 Mutants Limited molecular responses Patient convenience, efficacy in non-Type 1 mutants, and improved VAF reduction remain significant areas of unmet need Additional therapies needed to fully maximize the CALR opportunity for patients New treatments are needed that are equipotent against all CALR mutations and deliver disease modifying activity at lower, well-tolerated doses. 1. Mascarenhas 2025 (ASH); ClinicalTrials.gov/NCT07623200 (A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia) 2. Incyte investor presentations; 3. High volume on-body injection (OBI) device in development, along with recently announced collaboration to explore subcutaneous dosing enabled by Halozyme ENHANZE® technology. Initial clinical profile of INCA’989 established in Phase 1/2 trial 1:


Slide 31

Degrader Antibody Conjugates (DACs) Represent the Next Generation of ADCs For a review of next generation ADC payloads, see Fu, Z., Li, S., Han, S. et al. Sig Transduct Target Ther 7, 93 (2022).  Property Traditional ADC Precision DAC Potency Antibody Selectivity Payload Selectivity PD Marker - Payload Non-Genotoxic X X X Targeted Protein Degraders (TPDs) are an Emerging Payload Class for ADCs in the Clinic* * Morris, J. Beacon ADC by HansonWade. “Analyzing the ADC Boom: Landscape Review.” World ADC (San Diego). November 2024. Denotes Payload MOA for clinical stage assets currently in development at time of analysis. DACs have potential to deliver both improved efficacy and tolerability over traditional ADCs


Slide 32

mCALR-Targeted DACs Offer a Differentiated Approach to Eradicating CALR Mutant Clones SMARCA2/4 Degrader Naked antibodies bind to the target impacting signaling and proliferation, but do not have the selective mutant cell killing potential of a DAC SMARCA2/4 degraders are highly active in mCALR MPN cell lines and can be used as highly potent payloads for mCALR-targeted DACs1 Prelude’s mCALR x SMARCA2/4 DACs could represent a best-in-category approach with disease modifying potential 1. Prelude Data on File; Fultang N., et al., EHA2025 Oral Abstract, 12 June 25; Discovery Of First-in-class Precision ADCs Targeting Mutant Calreticulin For The Treatment Of MPNs. (access here);


Slide 33

Prelude is Advancing mCALR DACs Equipotent for Type 1 & 2 Mutations On Track to Nominate Development Candidate by YE 2026 >68x Selective Cytotoxicity in vitro Robust Tumor Growth Inhibition in vivo Fultang N., et al., EHA2025 Oral Abstract, 12 June 25; Discovery Of First-in-class Precision ADCs Targeting Mutant Calreticulin For The Treatment Of MPNs. (access here); Reis, et al. Blood. 2024;144(22):2336 CALR x SMARCA2/4 DAC mCALR x SMARCA2/4 DAC Prelude DACs Naked Ab (‘989) ~100x Better Potency 100X Better potency than INCA989 at low, well tolerated doses Selective cytotoxicity and robust tumor growth inhibition at well-tolerated doses in vivo Potential for low volume subcutaneous administration mCALR DAC (µg/mL)


Slide 34

Executive Summary First-in-class KAT6A selective degrader (PRT13722) in the clinic with potential to demonstrate differentiated efficacy and safety over KAT6A/B inhibitors; initial POC data anticipated 2nd Half 2027 JAK2V617F mutant selective inhibitor (PRT12396) IND cleared and Phase 1 study enrollment underway with potential Incyte option exercise decision by 1H 2027 1 Novel mCALR precision DAC program advancing to DC nomination by YE 2026 with potential to deliver improved disease modifying efficacy over mCALR-targeted antibodies Continued investment in foundational discovery engine poised to deliver future pipeline of potential practice-changing cancer medicines in areas of high unmet need Current cash runway expected into second quarter of 2028 1 - Subject of exclusive option agreement with Incyte (announced November 2025)


Slide 35

Thank You Contact Us: Robert Doody SVP, Investor Relations rdoody@preludetx.com

Filing Exhibits & Attachments

3 documents

Keep reading